Hormone receptor-positive, HER2-negative breast cancer (HR+/HER2- BC) represents a significant fraction of all breast cancer diagnoses. While conventional treatment with endocrine therapy (ET) and CDK4/6 inhibitors has improved clinical outcomes, the developmentRead More…
Today, when talking about cancer color change, pancreatic cancer can be said to be a “tough role” in cancer. It is highly malignant and ranks seventh in the world. Among them, pancreaticRead More…
“If the first generation of ADCs were rifles, the new wave is starting to look like programmable cruise missiles.” —Anonymous medicinal chemist at a recent Keystone symposium In the decade since brentuximabRead More…
Antibody-Oligonucleotide Conjugates (AOCs) represent a new medical frontier which emerged through the integration of antibody technology with nucleic acid therapies. These hybrid molecules which integrate monoclonal antibodies precision with oligonucleotides gene-editing ability areRead More…
The field of antibody-drug conjugates (ADCs) is experiencing a major transformation due to the development of bispecific ADCs (BsADCs) that merge the dual-targeting functionality of bispecific antibodies (BsAbs) with the cell-killing powerRead More…
Among all emerging technologies for cancer therapy, one is both highly accurate and efficient: Antibody-Drug Conjugates (ADCs). These missiles are the first such missiles that allow us to kill cancer cells while doingRead More…
The cure of cancer is not the only goal on the table and the very best are antibody-drug conjugates. These innovative drugs combine monoclonal antibodies with cytotoxic chemotherapies to deliver highly targetedRead More…
Bacterial infections are one of the most serious threats to human health, causing millions of deaths worldwide every year. However, due to the emergence of bacterial resistance, the antibacterial activity of manyRead More…
Intracellular proteins can be degraded, processed, and presented on the cell surface in complex with MHC molecules (HLA), which can be specifically recognized by TCR (Figure 1). Antibodies that recognize pMHC likeRead More…
Recently, combining immunotherapy with ADCs has entered clinical research, with growing evidence that ADCs may increase the efficacy of immunotherapy. Its mechanisms are varied, including inducing immunogenic cell death, dendritic cell maturation,Read More…